Emami Limited
Emami Limited (EMAMILTD.BO) Stock Competitors & Peer Comparison
See (EMAMILTD.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Household & Personal Products Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMAMILTD.BO | ₹398.15 | +1.36% | 173.8B | 21.88 | ₹18.20 | +3.01% |
| HINDUNILVR.NS | ₹2,065.30 | +0.03% | 4.9T | 48.07 | ₹42.96 | +2.08% |
| HINDUNILVR.BO | ₹2,065.00 | +0.03% | 4.9T | 44.66 | ₹46.24 | +2.08% |
| GODREJCP.BO | ₹994.85 | -0.25% | 1T | 55.86 | ₹17.81 | +1.96% |
| GODREJCP.NS | ₹994.80 | -0.28% | 1T | 55.86 | ₹17.81 | +1.96% |
| MARICO.BO | ₹761.55 | +2.46% | 986.4B | 57.69 | ₹13.20 | +1.38% |
| MARICO.NS | ₹761.35 | +2.26% | 986.2B | 57.46 | ₹13.25 | +1.38% |
| DABUR.NS | ₹417.25 | +0.55% | 740.1B | 40.20 | ₹10.38 | +1.92% |
| DABUR.BO | ₹417.10 | +0.47% | 739.8B | 40.22 | ₹10.37 | +1.92% |
| COLPAL.NS | ₹1,829.50 | +0.54% | 497.6B | 37.51 | ₹48.77 | +2.79% |
Stock Comparison
EMAMILTD.BO vs HINDUNILVR.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, HINDUNILVR.NS has a market cap of 4.9T. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while HINDUNILVR.NS trades at ₹2,065.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas HINDUNILVR.NS's P/E ratio is 48.07. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to HINDUNILVR.NS's ROE of +0.29%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to HINDUNILVR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check HINDUNILVR.NS's competition here
EMAMILTD.BO vs HINDUNILVR.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, HINDUNILVR.BO has a market cap of 4.9T. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while HINDUNILVR.BO trades at ₹2,065.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas HINDUNILVR.BO's P/E ratio is 44.66. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to HINDUNILVR.BO's ROE of +0.29%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to HINDUNILVR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check HINDUNILVR.BO's competition here
EMAMILTD.BO vs GODREJCP.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, GODREJCP.BO has a market cap of 1T. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while GODREJCP.BO trades at ₹994.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas GODREJCP.BO's P/E ratio is 55.86. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to GODREJCP.BO's ROE of +0.15%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to GODREJCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check GODREJCP.BO's competition here
EMAMILTD.BO vs GODREJCP.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, GODREJCP.NS has a market cap of 1T. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while GODREJCP.NS trades at ₹994.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas GODREJCP.NS's P/E ratio is 55.86. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to GODREJCP.NS's ROE of +0.15%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to GODREJCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check GODREJCP.NS's competition here
EMAMILTD.BO vs MARICO.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, MARICO.BO has a market cap of 986.4B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while MARICO.BO trades at ₹761.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas MARICO.BO's P/E ratio is 57.69. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to MARICO.BO's ROE of +0.40%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to MARICO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check MARICO.BO's competition here
EMAMILTD.BO vs MARICO.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, MARICO.NS has a market cap of 986.2B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while MARICO.NS trades at ₹761.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas MARICO.NS's P/E ratio is 57.46. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to MARICO.NS's ROE of +0.40%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to MARICO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check MARICO.NS's competition here
EMAMILTD.BO vs DABUR.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, DABUR.NS has a market cap of 740.1B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while DABUR.NS trades at ₹417.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas DABUR.NS's P/E ratio is 40.20. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to DABUR.NS's ROE of +0.17%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to DABUR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check DABUR.NS's competition here
EMAMILTD.BO vs DABUR.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, DABUR.BO has a market cap of 739.8B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while DABUR.BO trades at ₹417.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas DABUR.BO's P/E ratio is 40.22. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to DABUR.BO's ROE of +0.17%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to DABUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check DABUR.BO's competition here
EMAMILTD.BO vs COLPAL.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, COLPAL.NS has a market cap of 497.6B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while COLPAL.NS trades at ₹1,829.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas COLPAL.NS's P/E ratio is 37.51. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to COLPAL.NS's ROE of +0.81%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to COLPAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check COLPAL.NS's competition here
EMAMILTD.BO vs COLPAL.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, COLPAL.BO has a market cap of 497.4B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while COLPAL.BO trades at ₹1,828.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas COLPAL.BO's P/E ratio is 37.42. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to COLPAL.BO's ROE of +0.81%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to COLPAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check COLPAL.BO's competition here
EMAMILTD.BO vs PGHH.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, PGHH.BO has a market cap of 316.9B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while PGHH.BO trades at ₹9,763.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas PGHH.BO's P/E ratio is 44.11. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to PGHH.BO's ROE of +1.03%. Regarding short-term risk, EMAMILTD.BO and PGHH.BO have similar daily volatility (3.63).Check PGHH.BO's competition here
EMAMILTD.BO vs PGHH.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, PGHH.NS has a market cap of 316.7B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while PGHH.NS trades at ₹9,757.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas PGHH.NS's P/E ratio is 44.16. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to PGHH.NS's ROE of +1.03%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to PGHH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check PGHH.NS's competition here
EMAMILTD.BO vs GILLETTE.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, GILLETTE.NS has a market cap of 246.6B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while GILLETTE.NS trades at ₹7,567.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas GILLETTE.NS's P/E ratio is 46.26. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to GILLETTE.NS's ROE of +0.58%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to GILLETTE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check GILLETTE.NS's competition here
EMAMILTD.BO vs GILLETTE.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, GILLETTE.BO has a market cap of 246.4B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while GILLETTE.BO trades at ₹7,562.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas GILLETTE.BO's P/E ratio is 46.17. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to GILLETTE.BO's ROE of +0.58%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to GILLETTE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check GILLETTE.BO's competition here
EMAMILTD.BO vs EMAMILTD.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, EMAMILTD.NS has a market cap of 173.9B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while EMAMILTD.NS trades at ₹398.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas EMAMILTD.NS's P/E ratio is 21.87. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to EMAMILTD.NS's ROE of +0.29%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to EMAMILTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check EMAMILTD.NS's competition here
EMAMILTD.BO vs CUPID.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, CUPID.BO has a market cap of 117.8B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while CUPID.BO trades at ₹87.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas CUPID.BO's P/E ratio is 141.27. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to CUPID.BO's ROE of +0.24%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to CUPID.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check CUPID.BO's competition here
EMAMILTD.BO vs CUPID.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, CUPID.NS has a market cap of 117.7B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while CUPID.NS trades at ₹87.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas CUPID.NS's P/E ratio is 141.19. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to CUPID.NS's ROE of +0.24%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to CUPID.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check CUPID.NS's competition here
EMAMILTD.BO vs HONASA.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, HONASA.BO has a market cap of 99.2B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while HONASA.BO trades at ₹304.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas HONASA.BO's P/E ratio is 63.93. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to HONASA.BO's ROE of +0.13%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to HONASA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check HONASA.BO's competition here
EMAMILTD.BO vs HONASA.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, HONASA.NS has a market cap of 98.9B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while HONASA.NS trades at ₹304.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas HONASA.NS's P/E ratio is 63.73. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to HONASA.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to HONASA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check HONASA.NS's competition here
EMAMILTD.BO vs JYOTHYLAB.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, JYOTHYLAB.BO has a market cap of 76.5B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while JYOTHYLAB.BO trades at ₹208.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas JYOTHYLAB.BO's P/E ratio is 22.39. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to JYOTHYLAB.BO's ROE of +0.18%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to JYOTHYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check JYOTHYLAB.BO's competition here
EMAMILTD.BO vs JYOTHYLAB.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, JYOTHYLAB.NS has a market cap of 76.4B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while JYOTHYLAB.NS trades at ₹208.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas JYOTHYLAB.NS's P/E ratio is 22.32. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to JYOTHYLAB.NS's ROE of +0.18%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to JYOTHYLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check JYOTHYLAB.NS's competition here
EMAMILTD.BO vs BAJAJCON.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, BAJAJCON.NS has a market cap of 47.3B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while BAJAJCON.NS trades at ₹360.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas BAJAJCON.NS's P/E ratio is 30.94. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to BAJAJCON.NS's ROE of +0.22%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to BAJAJCON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check BAJAJCON.NS's competition here
EMAMILTD.BO vs BAJAJCON.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, BAJAJCON.BO has a market cap of 47.1B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while BAJAJCON.BO trades at ₹360.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas BAJAJCON.BO's P/E ratio is 30.89. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to BAJAJCON.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to BAJAJCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check BAJAJCON.BO's competition here
EMAMILTD.BO vs SHK.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, SHK.NS has a market cap of 16.7B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while SHK.NS trades at ₹120.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas SHK.NS's P/E ratio is 9.82. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to SHK.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to SHK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check SHK.NS's competition here
EMAMILTD.BO vs ALLTIME.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, ALLTIME.NS has a market cap of 13.2B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while ALLTIME.NS trades at ₹201.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas ALLTIME.NS's P/E ratio is 36.95. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to ALLTIME.NS's ROE of +0.08%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to ALLTIME.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check ALLTIME.NS's competition here
EMAMILTD.BO vs BCLIND.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, BCLIND.NS has a market cap of 8.6B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while BCLIND.NS trades at ₹29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas BCLIND.NS's P/E ratio is 7.31. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to BCLIND.NS's ROE of +0.14%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to BCLIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check BCLIND.NS's competition here
EMAMILTD.BO vs KAYA.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, KAYA.BO has a market cap of 4.1B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while KAYA.BO trades at ₹269.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas KAYA.BO's P/E ratio is -4.75. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to KAYA.BO's ROE of +0.62%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to KAYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check KAYA.BO's competition here
EMAMILTD.BO vs KAYA.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, KAYA.NS has a market cap of 4B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while KAYA.NS trades at ₹263.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas KAYA.NS's P/E ratio is -4.64. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to KAYA.NS's ROE of +0.62%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to KAYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check KAYA.NS's competition here
EMAMILTD.BO vs ADORMUL.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, ADORMUL.BO has a market cap of 1.3B. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while ADORMUL.BO trades at ₹135.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas ADORMUL.BO's P/E ratio is -29.80. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to ADORMUL.BO's ROE of -0.32%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to ADORMUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check ADORMUL.BO's competition here
EMAMILTD.BO vs PCCOSMA.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, PCCOSMA.BO has a market cap of 862.3M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while PCCOSMA.BO trades at ₹325.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas PCCOSMA.BO's P/E ratio is 10.76. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to PCCOSMA.BO's ROE of +0.16%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to PCCOSMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check PCCOSMA.BO's competition here
EMAMILTD.BO vs JHS.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, JHS.NS has a market cap of 681.4M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while JHS.NS trades at ₹7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas JHS.NS's P/E ratio is -12.63. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to JHS.NS's ROE of -0.03%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to JHS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check JHS.NS's competition here
EMAMILTD.BO vs JHS.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, JHS.BO has a market cap of 677.4M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while JHS.BO trades at ₹7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas JHS.BO's P/E ratio is -8.52. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to JHS.BO's ROE of -0.03%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to JHS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check JHS.BO's competition here
EMAMILTD.BO vs STDSFAC.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, STDSFAC.BO has a market cap of 420.9M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while STDSFAC.BO trades at ₹50.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas STDSFAC.BO's P/E ratio is N/A. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to STDSFAC.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.BO is less volatile compared to STDSFAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check STDSFAC.BO's competition here
EMAMILTD.BO vs NKIND.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, NKIND.BO has a market cap of 396.7M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while NKIND.BO trades at ₹66.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas NKIND.BO's P/E ratio is -6.41. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to NKIND.BO's ROE of +0.02%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to NKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check NKIND.BO's competition here
EMAMILTD.BO vs AMBICAAGAR.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, AMBICAAGAR.NS has a market cap of 386.7M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while AMBICAAGAR.NS trades at ₹22.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas AMBICAAGAR.NS's P/E ratio is 30.84. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to AMBICAAGAR.NS's ROE of +0.01%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to AMBICAAGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check AMBICAAGAR.NS's competition here
EMAMILTD.BO vs AMBICAAGAR.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, AMBICAAGAR.BO has a market cap of 384.6M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while AMBICAAGAR.BO trades at ₹22.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas AMBICAAGAR.BO's P/E ratio is 77.21. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to AMBICAAGAR.BO's ROE of +0.01%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to AMBICAAGAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check AMBICAAGAR.BO's competition here
EMAMILTD.BO vs NKIND.NS Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, NKIND.NS has a market cap of 369.1M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while NKIND.NS trades at ₹61.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas NKIND.NS's P/E ratio is -5.96. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to NKIND.NS's ROE of +0.02%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to NKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check NKIND.NS's competition here
EMAMILTD.BO vs NUWAY.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, NUWAY.BO has a market cap of 354.6M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while NUWAY.BO trades at ₹37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas NUWAY.BO's P/E ratio is 14.40. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to NUWAY.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.BO is more volatile compared to NUWAY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check NUWAY.BO's competition here
EMAMILTD.BO vs PAOS.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, PAOS.BO has a market cap of 292.4M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while PAOS.BO trades at ₹47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas PAOS.BO's P/E ratio is -9.05. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to PAOS.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to PAOS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check PAOS.BO's competition here
EMAMILTD.BO vs SATTVASUKU.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, SATTVASUKU.BO has a market cap of 272.4M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while SATTVASUKU.BO trades at ₹0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas SATTVASUKU.BO's P/E ratio is -71.00. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to SATTVASUKU.BO's ROE of +0.09%. Regarding short-term risk, EMAMILTD.BO is less volatile compared to SATTVASUKU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.BO.Check SATTVASUKU.BO's competition here
EMAMILTD.BO vs PARMCOS-B.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, PARMCOS-B.BO has a market cap of 172.4M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while PARMCOS-B.BO trades at ₹35.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas PARMCOS-B.BO's P/E ratio is 169.05. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to PARMCOS-B.BO's ROE of +0.00%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to PARMCOS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check PARMCOS-B.BO's competition here
EMAMILTD.BO vs HIPOLIN.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, HIPOLIN.BO has a market cap of 156.5M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while HIPOLIN.BO trades at ₹49.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas HIPOLIN.BO's P/E ratio is -4.99. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to HIPOLIN.BO's ROE of -0.35%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to HIPOLIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check HIPOLIN.BO's competition here
EMAMILTD.BO vs CORNE.BO Comparison April 2026
EMAMILTD.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.BO stands at 173.8B. In comparison, CORNE.BO has a market cap of 51.5M. Regarding current trading prices, EMAMILTD.BO is priced at ₹398.15, while CORNE.BO trades at ₹10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.BO currently has a P/E ratio of 21.88, whereas CORNE.BO's P/E ratio is -6.07. In terms of profitability, EMAMILTD.BO's ROE is +0.29%, compared to CORNE.BO's ROE of +0.09%. Regarding short-term risk, EMAMILTD.BO is more volatile compared to CORNE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.BO.Check CORNE.BO's competition here